Molecular Signatures of Lung Cancer

描述（由申请人提供）： 在美国，肺癌是癌症死亡的最常见原因，并且治疗非常无效，5年存活率低于15%。该申请提出了一个基于肺癌孢子计划的首要机构的合作伙伴关系，以确定如何从综合分子分析中获得的信息可以用于改善患者护理，并最终改善患者的预后。我们建议使用各种分子分析技术，包括DNA，RNA和蛋白质为基础的技术，解决诊断和预测签名已经开发的几个分子签名的潜在临床实用性进行评估。我们建议测试的诊断谱使用血清蛋白质组学来区分癌症患者和非癌症患者，目的是减少无效开胸手术的数量。我们建议测试的预测概况包括生存和隐匿性淋巴结状态的参与，用于风险评估，以及预测对化疗和EGFr靶向治疗的反应的基因组、cDNA和蛋白质组概况。 将鉴定蛋白质组学谱中的重要标志物，并与基因组和cDNA标志物一起开发临床可行的测定方法，并在前瞻性研究中测试其稳健性。

DESCRIPTION (provided by applicant): Lung cancer is the most common cause of cancer death in the United States and is very ineffectively treated, with a less than 15% 5 year survival. This application proposes a partnering of premiere institutions based in the Lung Cancer SPORE program to determine how the information derived from comprehensive molecular analyses can be used to improve patient care and ultimately, patient outcomes. We propose to evaluate the potential clinical usefulness of several molecular signatures already developed using a variety of molecular analysis technologies, including DNA, RNA and protein-based technologies addressing both diagnostic and predictive signatures. The diagnostic profile we propose to test uses serum proteomics to discriminate patients with cancer from those without cancer with goal to reduce the number of futile thoracotomies. The predictive profiles we propose to test include survival and occult nodal status involvement, useful for in risk assessment, and genomic, cDNA and proteomic profiles predicting response to chemotherapy and EGFr targeted therapeutics. Important markers in proteomic profiles will be identified, and together with genomic and cDNA markers, clinically feasible assays will be developed and their robustness tested in prospective studies.